Evidence map›Paper›PMID 39954187›Full record

ReviewInflammopharmacology2025

Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions.

Yan Zhang, Shaoying Yuan, Yixing Wu, Wenkai Nie, Tianhui You, Huiwen Yang, Bing Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan ZhangCollege of Pharmacy, Guangzhou Higher Education Mega Center, Guangdong Pharmaceutical University, 280 Wai Huan Dong Road, Guangzhou, 510006, China.
Shaoying YuanCollege of Nursing, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Yixing WuCollege of Nursing, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Wenkai NieCollege of Pharmacy, Guangzhou Higher Education Mega Center, Guangdong Pharmaceutical University, 280 Wai Huan Dong Road, Guangzhou, 510006, China.
Tianhui YouCollege of Continuing Education, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Huiwen YangCollege of Pharmacy, Guangzhou Higher Education Mega Center, Guangdong Pharmaceutical University, 280 Wai Huan Dong Road, Guangzhou, 510006, China.
Bing LiuCollege of Pharmacy, Guangzhou Higher Education Mega Center, Guangdong Pharmaceutical University, 280 Wai Huan Dong Road, Guangzhou, 510006, China. liubing520@gdpu.edu.cn.ORCID http://orcid.org/0000-0002-3144-5673

Funding

Guangzhou key laboratory of construction and application of new drug screening model systems 201805010006Key Laboratory of New Drug Discovery and Evaluation of ordinary universities of Guangdong province 2017KSYS002National Key Clinical Specialty Discipline Construction Program of China Z155080000004
6 · The paper itself

Abstract

Atopic dermatitis (AD) is a complex chronic inflammatory skin disorder, with its incidence significantly increasing in recent years. The pathogenesis of AD is complex, involving multiple factors such as genetic susceptibility, dysbiosis of the skin microbiome, autoimmune abnormalities, impaired epidermal barrier function, and environmental factors. These factors collectively contribute to the high incidence of the disease and its significant socio-economic burden. This article reviews the pathogenesis of AD and analyzes the current traditional treatment approaches, including topical and systemic therapies, highlighting the issues they face. It focuses on the current status and treatment strategies. Specifically, as the significant heterogeneity of AD, treatment paradigms are gradually shifting from a "one-size-fits-all" approach to personalized treatments. The aim is to achieve more effective management of AD and address the issues arising from individual differences. Through these discussions, this article aims to provide new perspectives and strategies for the clinical treatment of AD, in order to reduce the disease burden on patients.

Indexed as

Dermatitis, AtopicDermatologic AgentsAnimalsHumansSkinDermatologic AgentsAtopic dermatitisPersonalized treatmentPrecision medicineTreatment strategies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.